Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.

Genentech, University of Cambridge and Babraham Bioscience Technologies have backed accelerator Start Codon, which plans to work with some 50 life sciences startups.

Amgen is among the seed investors for Stanford-licensed drug release technology developer Navan Technologies, which hopes its nanoinjection technique will enable more cell and gene therapies to be produced at scale.

Allied Minds will focus on funding existing companies after exiting the red to bank a $47.3m net profit for 2018.

The RNAi therapeutics developer increased its series C funding to $47m following a second tranche led by corporate joint venture CR-CP Life Sciences Fund.

The cell culture medium developer has reeled in $14.9m from investors including strategic partner WuXi Biologics in its series A-plus round.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

3D printing technology producer Carbon, which counts more than half a dozen corporates as investors, has filed to raise $300m in equity financing.

UC Riverside has sealed an MOU with incubator Murrieta Genomics to drive its genomics research and build links between the innovation ecosystems of both parties.